Stemson’s Cornerstone Patent Approved in US
Stemson Therapeutics announced approval in the United States of US patent No. 10716808, entitled “Methods and compositions to modulate hair growth” licensed exclusively from the Sanford Burnham Prebys Medical Discovery Institute. The patent covers a novel process developed by Stemson co-founder and Chief Scientific Officer, Alexey Terskikh, PhD, to differentiate Induced Pluripotent Stem Cells (iPSC) into dermal papilla cells, the cell type primarily responsible for controlling hair follicle generation and hair cycling. Issuance of this foundational patent provides stability surrounding the company’s efforts to develop its breakthrough iPSC-based solution for hair growth.
“We are pleased with the approval of this cornerstone patent in the US,” said Prof. Terskikh. “The process of human iPSC differentiation into Dermal Papilla cells serves as the very foundation for our solution to generate new hair follicles to treat patients suffering from hair loss. Patent protection adds more certainty to our development roadmap leading toward human clinical trials.”
The company has filed for patent approval in additional countries to support its global commercialization plan in the future.